Skip to main content
. Author manuscript; available in PMC: 2011 Mar 15.
Published in final edited form as: Arthritis Rheum. 2010 Feb;62(2):542–552. doi: 10.1002/art.27221

Figure 2. Serologic changes.

Figure 2

a. Anti-dsDNA levels decreased during treatment mainly in the medium/high dose group.

b. The proportional change in anti-dsDNA levels was substantially higher than the small non-significant decrease in IgG levels, especially in the medium/high dose group. Only patients with anti-dsDNA at baseline are included in this analysis. 1n=13 for the entire cohort, 2n=9 medium/high dose group.

Box plots show the 10th, 25th, 50th (median), 75th and 90th percentiles. Values above the 90th and below the 10th percentile are plotted as points. (End of treatment values were compared to baseline by the Wilcoxon signed rank test)